News about 'innovations'

Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012 Feb 19...

Click here to go to the Global Health Trials website. We would like to share an exciting development in the field of global health, which has been launched in the last six months – an innovative professional membership scheme for tracking the continued professional development of clinical research...

Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King M, Serhan CN, Ramakrishnan L. Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections. Cell. 2012 Feb 3;...

The 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, Janu a ry 29th with the official opening ceremony held yesterday January 30th. Below are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the...

Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother. 2012 Jan 17. [Epub ahead of print] In this week’s article, we look at two drugs in our Global TB Drug Pipeline...

Click here for brochure. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012 Jan;16(1):...

The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis (TB). The campaign began in 2009 in South Africa and has been so successful that other countries in Africa and Asia are taking...

Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis . Cell Host Microbe. 2011 Nov 17;10(5):475-85. This week’s article...

2011 WGND Annual Meeting (Lille, France) During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference . There were several updates to the Global TB Drugs Pipeline showing progress toward...

Dr. Sanjib Bhakta Summary: This week’s interview is with Dr. Sanjib Bhakta who is a Senior Lecturer in Microbiology at Birkbeck, University of London. In the interview, we discuss his work in screening for potential candidates for anti-tuberculosis treatment. Dr. Bhakta’s Laboratory has developed...

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB...

pyrazinamide (PZA) Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE 3rd, Wang H, Zhang W, Zhang Y. Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis . Science. 2011 Aug 11. [Epub ahead of print] This week we highlight an article published out of Ying Zhang’s laboratory at Johns...

Silva RF, Mendonc SCM, Carvalho LM, Reis AM, Gordo I, Trindade S, Dionisio F. Pervasive Sign Epistasis between Conjugative Plasmids and Drug-Resistance Chromosomal Mutations. PLoS Genetics. 2011 July;7(7):1-10. This week we have an article by researchers from Portugal that suggests that in the case...

Dr. Armand Van Deun Summary: This week’s interview is with Dr. Armand Van Deun who was the recipient of the 2010 Stop TB Partnership-Kochon Foundation prize . Last year, Dr. Van Deun, et al., published an article in the American Journal of Respiratory and Critical Care Medicine entitled “ Short,...

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri . The candidate was developed by the University of Zaragoza , Spain and is part of the...